CN114358939A - Method and device for monitoring hot spot information in pharmaceutical industry, electronic equipment and storage medium - Google Patents
Method and device for monitoring hot spot information in pharmaceutical industry, electronic equipment and storage medium Download PDFInfo
- Publication number
- CN114358939A CN114358939A CN202111665276.8A CN202111665276A CN114358939A CN 114358939 A CN114358939 A CN 114358939A CN 202111665276 A CN202111665276 A CN 202111665276A CN 114358939 A CN114358939 A CN 114358939A
- Authority
- CN
- China
- Prior art keywords
- information
- hot spot
- preset
- hotspot
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012544 monitoring process Methods 0.000 title claims abstract description 51
- 238000000034 method Methods 0.000 title claims abstract description 45
- 238000003860 storage Methods 0.000 title claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 180
- 229940079593 drug Drugs 0.000 claims abstract description 67
- 238000012827 research and development Methods 0.000 claims description 20
- 238000004590 computer program Methods 0.000 claims description 12
- 229940042040 innovative drug Drugs 0.000 claims description 8
- 238000012806 monitoring device Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 7
- 238000004891 communication Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 238000003255 drug test Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000009520 phase I clinical trial Methods 0.000 description 2
- 238000009521 phase II clinical trial Methods 0.000 description 2
- 238000009522 phase III clinical trial Methods 0.000 description 2
- LXZMHBHEXAELHH-UHFFFAOYSA-N 4-[6-methoxy-4-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)pyridin-2-yl]benzoic acid Chemical compound N=1C(OC)=CC(C(=O)N2CCC3(CC2)CC(=O)C=2N(C(C)C)N=CC=2C3)=CC=1C1=CC=C(C(O)=O)C=C1 LXZMHBHEXAELHH-UHFFFAOYSA-N 0.000 description 1
- 206010008723 Chondrodystrophy Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000008919 achondroplasia Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000009960 carding Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940125005 clesacostat Drugs 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000012362 drug development process Methods 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- ANSXAPJVJOKRDJ-UHFFFAOYSA-N furo[3,4-f][2]benzofuran-1,3,5,7-tetrone Chemical compound C1=C2C(=O)OC(=O)C2=CC2=C1C(=O)OC2=O ANSXAPJVJOKRDJ-UHFFFAOYSA-N 0.000 description 1
- 238000011194 good manufacturing practice Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Images
Abstract
The invention provides a method and a device for monitoring hot spot information in the pharmaceutical industry, electronic equipment and a storage medium, wherein the method comprises the following steps: acquiring medicine information of a target medicine enterprise; monitoring a preset hot spot information element based on the medicine information, and marking the hot spot information element at the current time if the hot spot information element belongs to a first preset hot spot information set; if the hotspot information element belongs to a second preset hotspot information set, acquiring a predicted time increment value corresponding to the target hotspot information element, and marking the hotspot information element based on the starting time of the hotspot information element in the second preset hotspot information set and the predicted time increment value; the method, the device, the electronic equipment and the storage medium provided by the invention can clearly, accurately and completely comb product pipelines of medical innovation marketing enterprises, can carry out real-time monitoring and prospective prediction on hot spot information related to medicines influencing stock prices of target innovation medical marketing enterprises, and are convenient for investors to make corresponding preparations before stock price information fluctuates severely.
Description
Technical Field
The invention relates to the technical field of information monitoring, in particular to a method and a device for monitoring hot spot information in the pharmaceutical industry, electronic equipment and a storage medium.
Background
Since 2015, the pharmaceutical industry of China came to have exploded waves of innovation. By 6 months in 2021, the pharmaceutical industry in China has attracted the social financing of 1.5 trillion Renminbi in the past six years, reaching an unprecedented height. Particularly, the opening of the hong Kong biomedical boards and the scientific creation boards is a non-profit pharmaceutical innovation enterprise to open up capital withdrawal and a new financing channel. Under this background, a large number of pharmaceutical innovation enterprises are successively and successfully listed, and the pharmaceutical board has become an indispensable investment track in the secondary market.
The valuation given to the capital market of traditional pharmaceutical enterprises is usually based on the financial basic surface, namely, the indexes of sales income, net profit and the like. The financial indexes are secrets of enterprises and are not disclosed to the outside, investors can only follow up investment according to announcements of listed enterprises, and the advantage of information asymmetry is difficult to occur.
Disclosure of Invention
The invention provides a method and a device for monitoring hot spot information in the pharmaceutical industry, electronic equipment and a storage medium, which are used for solving the problems that product pipelines of enterprises marketing innovative medicines cannot be monitored and hot events and time related to medicines influencing stock price fluctuation cannot be forecasted in a prospective mode in the prior art.
The invention provides a method for monitoring hot spot information in the pharmaceutical industry, which comprises the following steps:
acquiring medicine information of a target medicine enterprise;
monitoring a preset hot spot information element based on the medicine information, and marking the hot spot information element at the current time if the hot spot information element belongs to a first preset hot spot information set; and if the hotspot information element belongs to a second preset hotspot information set, acquiring a predicted time increment value corresponding to the target hotspot information element, and marking the hotspot information element based on the starting time of the hotspot information element in the second preset hotspot information set and the predicted time increment value.
According to the monitoring method for hotspot information in pharmaceutical industry provided by the invention, the acquiring of the drug information of the target pharmaceutical enterprise comprises the following steps:
acquiring a marketed medical enterprise as a target medical enterprise based on a pre-constructed medical enterprise dictionary;
acquiring medicine information in research and development of a target medicine enterprise and marketed medicine information;
and acquiring core medicine information of the target medicine enterprise based on the medicine information in research and development and the marketed medicine information.
According to the monitoring method of the hot spot information in the pharmaceutical industry provided by the invention, the core medicine information comprises the following steps:
innovative drug information obtained based on drug information in research and development;
acquiring the market sales amount information of the marketed medicine, and acquiring the medicine information of which the sales amount ratio exceeds a preset threshold value based on the market sales amount information of the medicine.
According to the monitoring method for the hot spot information in the pharmaceutical industry provided by the invention, if the hot spot information element belongs to a first preset hot spot information set, the hot spot information element is marked by the current time, and the method comprises the following steps:
acquiring a hotspot information element in first preset hotspot information based on a preset time interval, and marking the target hotspot information element at the time acquired by the target hotspot information element;
according to the method for monitoring hot spot information in the pharmaceutical industry provided by the invention, if the hot spot information element belongs to a second preset hot spot information set, a predicted time increment value corresponding to a target hot spot information element is obtained, and the hot spot information element is marked based on the start time of the hot spot information element in the second preset hot spot information set and the predicted time increment value, the method comprises the following steps:
acquiring the starting time of the hotspot information element in the second preset hotspot information based on the marking time of the hotspot information element in the first preset hotspot information;
acquiring similar medicine information of target medicine information, and acquiring a predicted time increment value of a hotspot information element in second preset hotspot information based on historical data of the similar medicine information time increment value;
and marking the hot spot information elements in the second preset hot spot information based on the starting time and the predicted time increment of the hot spot information elements in the second preset hot spot information.
According to the monitoring method of the hot spot information in the pharmaceutical industry, provided by the invention, the hot spot information element in the first preset hot spot information is at least one element in hot events of transaction, clinical application, clinical test starting, marketing application and influence on sale;
and the hotspot information element in the second preset hotspot information is at least one element of clinical approval, clinical trial ending and approval marketing.
The method for monitoring hot spot information in the pharmaceutical industry is characterized by further comprising the following steps:
and pushing the hotspot information elements and the associated information thereof in the first preset hotspot information at the current marking time.
And pushing the hotspot information elements and the associated information thereof in the second preset hotspot information in a calendar mark mode.
The invention also provides a device for monitoring hot spot information in the pharmaceutical industry, which comprises:
an information acquisition module: acquiring medicine information of a target medicine enterprise;
the information monitoring module: monitoring a preset hot spot information element based on the medicine information, and marking the hot spot information element at the current time if the hot spot information element belongs to a first preset hot spot information set; and if the hotspot information element belongs to a second preset hotspot information set, acquiring a predicted time increment value corresponding to the target hotspot information element, and marking the hotspot information element based on the starting time of the hotspot information element in the second preset hotspot information set and the predicted time increment value.
The invention also provides an electronic device, which comprises a memory, a processor and a computer program stored on the memory and capable of running on the processor, wherein the processor implements the steps of any one of the above methods for monitoring hot spot information in the pharmaceutical industry when executing the computer program.
The present invention also provides a non-transitory computer readable storage medium, on which a computer program is stored, which when executed by a processor, implements the steps of the method for monitoring medical industry hotspot information as described in any one of the above.
The method, the device, the electronic equipment and the storage medium for monitoring the hot information in the pharmaceutical industry clearly, accurately and completely comb product pipelines of pharmaceutical innovation marketing enterprises, perform real-time monitoring and prospective prediction on hot information related to medicines which affect stock prices of target innovation pharmaceutical marketing enterprises, and facilitate investors to make corresponding preparations before stock price information fluctuates severely.
Drawings
In order to more clearly illustrate the technical solutions of the present invention or the prior art, the drawings needed for the description of the embodiments or the prior art will be briefly described below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and those skilled in the art can also obtain other drawings according to the drawings without creative efforts.
Fig. 1 is a schematic flow chart of a method for monitoring hot spot information in the pharmaceutical industry according to the present invention;
fig. 2 is a schematic structural diagram of a monitoring device for hot spot information in the pharmaceutical industry according to the present invention;
fig. 3 is a schematic structural diagram of an electronic device provided in the present invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention clearer, the technical solutions of the present invention will be clearly and completely described below with reference to the accompanying drawings, and it is obvious that the described embodiments are some, but not all embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The invention is described in detail below with reference to the figures and specific embodiments.
Since 2015, the pharmaceutical industry of China came to have exploded waves of innovation. By 6 months in 2021, the pharmaceutical industry in China has attracted the social financing of 1.5 trillion Renminbi in the past six years, reaching an unprecedented height. Particularly, the opening of the hong Kong biomedical boards and the scientific creation boards is a non-profit pharmaceutical innovation enterprise to open up capital withdrawal and a new financing channel. Under this background, a large number of pharmaceutical innovation enterprises are successively and successfully listed, and the pharmaceutical board has become an indispensable investment track in the secondary market.
The valuation given to the capital market of traditional pharmaceutical enterprises is usually based on the financial basic surface, namely, the indexes of sales income, net profit and the like. The financial indexes are secrets of enterprises and are not disclosed to the outside, investors can only follow up investment according to announcements of listed enterprises, and the advantage of information asymmetry is difficult to occur.
Most of the innovative medicine marketing enterprises which come into the market in recent years are loss enterprises, the research and development investment is huge, the enterprise valuation is often unrelated to the sales income, and the valuation given by investors mainly comes from the innovative product pipelines. However, the research and development activities of the pharmaceutical innovation enterprises have high uncertainty, and there is a possibility of over-expectation or failure in research and development. The scientific plate is added to allow day fluctuation of +/-20%, and the hong Kong capital market does not limit the day price fluctuation interval. The stock price of the listed enterprises is often in drastic fluctuation along with the disclosure of the message surface, and the profit of investors is greatly influenced.
In conclusion, it is highly desirable to clearly, accurately and completely sort the product pipelines of the pharmaceutical innovation marketing enterprises, and to perform real-time monitoring and prospective prediction on the hot spot information related to the drugs which affects the stock prices of the target innovation pharmaceutical marketing enterprises.
Fig. 1 is a schematic flow chart of a method for monitoring hot spot information in the pharmaceutical industry, as shown in fig. 1, the method includes:
step 110: acquiring medicine information of a target medicine enterprise;
here, the target medical enterprise is a marketed medical enterprise, and specifically, the marketed medical enterprise may be acquired as the target medical enterprise based on a pre-constructed medical enterprise dictionary;
in detail, the pre-constructed medical enterprise dictionary at least includes an enterprise name, an enterprise listing type, such as:
| name of an enterprise | Type of business appearing |
| Beijing health (stock control) limited enterprise | Gang |
| Shenzhen city Bei relaxation science and technology stock limited enterprise | A strand |
| Guangzhou Taili biological medicine science and technology limited enterprise | Is not yet on the market |
For the innovative pharmaceutical marketing enterprises that have been on the market in recent years, the valuations given to them by investors mainly come from their innovative product pipelines. However, the research and development activities of the medical innovation enterprises have high uncertainty, the possibility of over-expectation or research and development failure exists, the stock price of the enterprises on the market often fluctuates sharply along with the disclosure of the message surface, and the influence on the income of investors is great;
therefore, clear, accurate and complete carding of product pipelines of enterprises in medical innovation marketing is needed; wherein the product pipeline of the pharmaceutical enterprise comprises information of the developing medicines and information of the marketed medicines.
Considering that, there are thousands of product pipelines of large-scale marketed pharmaceutical enterprises, and the product pipelines may contain various types of developed drugs, including innovative drugs, imitation drugs, bio-analogs, etc., wherein the innovative drugs are drugs which are independently developed and owned by the target pharmaceutical enterprise, the bio-analogs are biological products which are "highly similar" to bio-patent drugs produced by the target pharmaceutical enterprise, and the imitation drugs are alternative drugs which are produced by the target pharmaceutical enterprise and have the same active ingredients, dosage forms, administration routes and therapeutic effects as the imitation drugs; however, the occurrence of hot spot information related to a drug, which is not corresponding to any drug, may have a great influence on the stock price of the target pharmaceutical enterprise;
therefore, core medicine information of a target medicine enterprise is obtained based on the medicine information in research and development and the medicine information on the market; the core medicine information is medicine information which has great influence on stock price fluctuation of a target medicine enterprise;
it is considered that, on the one hand, for innovative pharmaceutical marketing enterprises that have been marketed in recent years, the valuations given to them by investors come mainly from their innovative product pipelines; on the other hand, the primary medicines of target medical enterprises are not all innovative medicines, and at present, the primary medicines of domestic large-scale marketing medical enterprises mostly take imitation medicines as main medicines;
thus, the core drug product comprises: innovative drug information obtained based on drug information in research and development; acquiring market sales information of marketed drugs, and acquiring drug information with sales ratio exceeding a preset threshold value based on the market sales information of the drugs;
in detail, in one aspect, a method of obtaining innovative drug information based on drug information in development includes:
medicine information in domestic research and development can be acquired based on CDE/ChiCTR, and medicine information, enterprise information, indication information and research and development stage information are extracted from the medicine information;
medicine information, enterprise information, indication information and research and development stage information can be acquired based on clinical registration platforms of various countries, papers published by enterprises, announcements published by enterprises, drug supervision institution disclosure information, listed company files, patents and other files;
matching in a pre-constructed enterprise dictionary to obtain a standard enterprise name based on the obtained enterprise information; matching in a pre-constructed medicine dictionary based on the acquired medicine information, wherein the medicine dictionary comprises but is not limited to medicine names and medicine innovation types; if the matching is not successful, the target medicine is possibly an innovative medicine which is being developed, the medicine innovation type of the target medicine is marked as 'innovative medicine', and the 'innovative medicine' is pushed to be checked manually, so that the accuracy of data is ensured; matching in the constructed indication dictionary based on the acquired indication information to obtain a standard indication name;
based on the steps, the information of the product pipeline under development of the target enterprise is obtained, for example:
| name of medicine | Name of an enterprise | Disease and disorder | Stage of research and development |
| clesacostat | Pfizer | Non-alcoholic steatohepatitis | Stage II clinics |
| recifercept | Pfizer | Achondroplasia | Stage II clinics |
| Prinbiri | Wyeth(Pfizer) | Dysmenorrhea; rheumatoid diseaseSexual arthritis; endometriosis of the endometrium | Stage II clinics |
| …… | …… | …… | …… |
In another aspect, a method of acquiring information on a marketing amount of a drug that has been marketed, the drug information having a sales ratio exceeding a preset threshold acquired based on the information on the marketing amount of the drug, includes:
acquiring over-year Drug marketing information tables including, but not limited to, Drug information, enterprise information, and indication information from each National Drug Administration official website, such as NMPA (National Drug Administration: National Drug Products Administration), FDA (american Food and Drug Administration), EMA (European Medicines Administration: European Medicines Administration), HMA (European Medicines Administration: Heads of Medicines Administration), PMDA (japanese Medical instruments approval), and the like;
matching in a pre-constructed enterprise dictionary to obtain a standard enterprise name based on the obtained enterprise information; based on the acquired medicine information, obtaining standard medicine name information in a pre-constructed medicine dictionary; matching in the constructed indication dictionary based on the acquired indication information to obtain a standard indication name;
based on the steps, the marketed product pipeline information of the target pharmaceutical enterprise is obtained, for example:
further, based on the information of the marketed drug of the target pharmaceutical enterprise, the sales information and the total sales of the target drug are obtained in the fiscal newspaper of the target pharmaceutical enterprise in a preset year, wherein the preset year may be 1 year, 2 years, or 5 years, and is not specifically limited in the embodiment of the present invention.
Based on the target medicine sales amount information and the total sales amount, medicine information that the ratio of the sales amount of the target medicine exceeds a preset threshold is obtained, where the preset threshold may be 30%, 40%, or 50%, and is not specifically limited in the embodiments of the present invention.
the research and development activities of medical innovation enterprises have high uncertainty, the possibility of over-expectation or research and development failure exists, the stock price of the listed companies often fluctuates violently along with the disclosure of a message surface, and the influence on the income of investors is great;
therefore, on the basis of clearly, accurately and completely combing product pipelines of medical innovation marketing enterprises, real-time monitoring and prospective prediction on hot spot information related to medicines influencing stock prices of target innovation medical marketing enterprises become important;
specifically, the method for marking the hot spot information element at the current time if the hot spot information element belongs to the first preset hot spot information set includes: acquiring a hotspot information element in first preset hotspot information based on a preset time interval, and marking the target hotspot information element at the time acquired by the target hotspot information element; the preset time interval may be 1 hour, 12 hours, or 24 hours, and is not particularly limited in the embodiment of the present invention.
If the hotspot information element belongs to a second preset hotspot information set, acquiring a predicted time increment value corresponding to the target hotspot information element, and marking the hotspot information element based on the start time of the hotspot information element in the second preset hotspot information set and the predicted time increment value, wherein the method comprises the following steps: acquiring the starting time of the hotspot information element in the second preset hotspot information based on the marking time of the hotspot information element in the first preset hotspot information; acquiring similar medicine information of target medicine information, and acquiring a predicted time increment value of a hotspot information element in second preset hotspot information based on historical data of the similar medicine information time increment value; marking hot spot information elements in the second preset hot spot information based on the starting time and the predicted time increment value of the hot spot information elements in the second preset hot spot information;
specifically, in this embodiment, for the research and development of innovative drugs, the new drug development milestones include preclinical research-clinical application-phase I-phase II-phase III-marketing application-marketing sale, and in the innovative drug development process, the disclosure of each milestone node strongly affects the fluctuation of stock prices, so each milestone node can be considered as a hot information element; considering that, on one hand, some pharmaceutical enterprises introduce new product pipelines from other enterprises by means of presence-in and further develop clinical trials, transaction information between pharmaceutical enterprises also needs to be included in the hot information elements; on the other hand, after the drug is sold on the market, because the sales volume and/or price of the target drug is increased or decreased rapidly due to the influence factors of the drug itself and/or the influence factors of the enterprise where the drug is located and/or the influence factors of the policy, etc., thereby affecting the sales volume of the target drug, the hot events affecting the sales also need to be included in the hot information elements, for example, the adverse reaction events are revealed after the target drug is sold on the market, the target drug is included in the medical insurance and/or collection, and the enterprise where the target drug is located is required to be certified by the gmp (good Manufacturing practice), etc., which are not specifically limited in the embodiment of the present invention.
Specifically, the hotspot information element in the first preset hotspot information is at least one element of hotspot events in the first preset hotspot information, such as transaction, clinical application, clinical test start, marketing application and marketing influence;
wherein the starting clinical trial includes, but is not limited to, starting phase I clinical trial, starting phase II clinical trial, starting phase III clinical trial;
the occurrence time of the hot spot element in the first preset hot spot information cannot be predicted, the target hot spot information element needs to be monitored and acquired in real time, and the target hot spot information element is marked according to the acquisition time of the target hot spot information element.
In detail, the preset time interval is used for acquiring hot information elements, medicine information and enterprise information including but not limited to hot information elements from a target enterprise official website, an official clinical registration information website, an official medicine evaluation information website, a medicine bidding and purchasing website, adverse reaction event announcements disclosed by FDA/MPA and medical insurance negotiation disclosure information;
standardizing the acquired hotspot element information, and matching the hotspot element information with a standard hotspot information element name after cleaning;
and matching the acquired medicine information and the enterprise information in a pre-constructed medicine dictionary and an enterprise dictionary to obtain standard medicine names and enterprise names.
And marking the target hotspot information element according to the time acquired by the target hotspot information element.
The hotspot information element in the second preset hotspot information is at least one element in clinical approval, clinical trial ending and approval marketing;
wherein the ending clinical trial includes, but is not limited to, ending phase I clinical trial, ending phase II clinical trial, ending phase III clinical trial;
the occurrence time of the hot spot element in the second preset hot spot information may be predicted, and the second hot spot information element may be marked based on the predicted time.
In more detail, the present invention is described in detail,
for approved clinical, approved marketing:
based on the marking time of the hotspot information element in the first preset hotspot information as clinical application and marketing application, respectively serving as the starting time of the hotspot information element in the second preset hotspot information as clinical approval and marketing approval;
acquiring the information of the same type of medicines of a target medicine, wherein the same type of medicines refer to medicines with the same attribute value, and the attribute value comprises but is not limited to a medicine type, an innovation type and an application item; the attribute value may be preset, or may be a preset attribute value of a drug, and the attribute value of the drug is calculated based on the correlation analysis to obtain the attribute value with high correlation, which is not specifically limited in the embodiment of the present invention.
Acquiring an evaluation cycle of each medicine in a medicine information set of the target medicine with the same attribute value; obtaining a predicted evaluation period of the target medicine according to the evaluation period of each medicine, wherein the predicted evaluation period of the target medicine can be an average number or a median number of evaluation periods of each medicine in a medicine information set with the same attribute value, and the embodiment of the invention is not specifically limited; the prediction evaluation period is a prediction time increment value;
a predicted date for the approved clinic is obtained based on the start time of the approved clinic and the predicted time delta value.
For the end of clinical trials:
marking time for each starting clinical trial stage based on a hotspot information element in the first preset hotspot information, and taking the marking time as corresponding starting time for ending the clinical trial stage in the second preset hotspot information;
the method includes the steps of obtaining information of similar drugs of a target drug, wherein the similar drugs refer to drugs with the same attribute value, the attribute value includes but is not limited to indication information, information of clinical trial recruiters, information of developing areas and information of sponsors, and the attribute value can be preset and is not limited in the embodiment of the invention.
Acquiring a test period of each medicine in a medicine information set with the same attribute value of a target medicine under a target clinical test stage; acquiring a predicted test period of a target drug according to a test period of each drug in a drug information set with the same attribute value in a target clinical test stage, wherein the predicted test period can be acquired based on an average number of each drug test period or a median of each drug test period, and is not specifically limited in the embodiment of the invention, and the predicted test period is a predicted time increment value;
an end time of the target clinical trial session is obtained based on the start time of the target clinical trial session and the predicted time increment value.
Further, carrying out information push on a hotspot information element and associated information thereof in the first preset hotspot information at the current marking time;
pushing the hotspot information elements and the associated information thereof in the second preset hotspot information in a calendar mark mode; the pushing in the form of calendar marks is information pushing in the form of electronic calendars and labels or links on the electronic calendars.
Wherein, the associated information includes but is not limited to standardized drug information, enterprise information and original text disclosing hotspot information elements.
The following describes a monitoring device for hot spot information in the pharmaceutical industry according to the present invention, and the monitoring device for hot spot information in the pharmaceutical industry described below and the monitoring method for hot spot information in the pharmaceutical industry described above may be referred to each other.
Fig. 2 is a schematic structural diagram of a monitoring device for hot spot information in the pharmaceutical industry provided by the present invention. As shown in fig. 2, the apparatus includes:
the information acquisition module 210: acquiring medicine information of a target medicine enterprise;
the information monitoring module 220: monitoring a preset hot spot information element based on the medicine information, and marking the hot spot information element at the current time if the hot spot information element belongs to a first preset hot spot information set; if the hotspot information element belongs to a second preset hotspot information set, acquiring a predicted time increment value corresponding to the target hotspot information element, and marking the hotspot information element based on the starting time of the hotspot information element in the second preset hotspot information set and the predicted time increment value;
according to the device provided by the embodiment of the invention, the medicine information of the target medicine enterprise is obtained; monitoring a preset hot spot information element based on the medicine information, and marking the hot spot information element at the current time if the hot spot information element belongs to a first preset hot spot information set; if the hot information element belongs to the second preset hot information set, acquiring a predicted time increment value corresponding to the target hot information element, marking the hot information element based on the start time of the hot information element in the second preset hot information set and the predicted time increment value, clearly, accurately and completely combing product pipelines of enterprises marketing the medical innovation, carrying out real-time monitoring and prospective prediction on hot information related to the medicines influencing the stock price of the enterprises marketing the medical innovation, and facilitating investors to make corresponding preparations before the stock price information fluctuates violently.
Fig. 3 illustrates a physical structure diagram of an electronic device, which may include, as shown in fig. 3: a processor (processor)310, a communication Interface (communication Interface)320, a memory (memory)330 and a communication bus 340, wherein the processor 310, the communication Interface 320 and the memory 330 communicate with each other via the communication bus 340. The processor 310 may invoke logic instructions in the memory 330 to perform a method for monitoring medical industry hotspot information, the method comprising: : acquiring medicine information of a target medicine enterprise; monitoring a preset hot spot information element based on the medicine information, and marking the hot spot information element at the current time if the hot spot information element belongs to a first preset hot spot information set; if the hotspot information element belongs to a second preset hotspot information set, acquiring a predicted time increment value corresponding to the target hotspot information element, and marking the hotspot information element based on the starting time of the hotspot information element in the second preset hotspot information set and the predicted time increment value;
in addition, the logic instructions in the memory 330 may be implemented in the form of software functional units and stored in a computer readable storage medium when the software functional units are sold or used as independent products. Based on such understanding, the technical solution of the present invention may be embodied in the form of a software product, which is stored in a storage medium and includes instructions for causing a computer device (which may be a personal computer, a server, or a network device) to execute all or part of the steps of the method according to the embodiments of the present invention. And the aforementioned storage medium includes: a U-disk, a removable hard disk, a Read-Only Memory (ROM), a Random Access Memory (RAM), a magnetic disk or an optical disk, and other various media capable of storing program codes.
In another aspect, the present invention also provides a computer program product, the computer program product comprising a computer program stored on a non-transitory computer-readable storage medium, the computer program comprising program instructions, which when executed by a computer, enable the computer to perform a method for monitoring hot spot information in the pharmaceutical industry, the method comprising: acquiring medicine information of a target medicine enterprise; monitoring a preset hot spot information element based on the medicine information, and marking the hot spot information element at the current time if the hot spot information element belongs to a first preset hot spot information set; and if the hotspot information element belongs to a second preset hotspot information set, acquiring a predicted time increment value corresponding to the target hotspot information element, and marking the hotspot information element based on the starting time of the hotspot information element in the second preset hotspot information set and the predicted time increment value.
In yet another aspect, the present invention also provides a non-transitory computer readable storage medium, on which a computer program is stored, the computer program being implemented by a processor to perform the method for monitoring hot spot information in the pharmaceutical industry, the method comprising: acquiring medicine information of a target medicine enterprise; monitoring a preset hot spot information element based on the medicine information, and marking the hot spot information element at the current time if the hot spot information element belongs to a first preset hot spot information set; and if the hotspot information element belongs to a second preset hotspot information set, acquiring a predicted time increment value corresponding to the target hotspot information element, and marking the hotspot information element based on the starting time of the hotspot information element in the second preset hotspot information set and the predicted time increment value.
The above-described embodiments of the apparatus are merely illustrative, and the units described as separate parts may or may not be physically separate, and parts displayed as units may or may not be physical units, may be located in one place, or may be distributed on a plurality of network units. Some or all of the modules may be selected according to actual needs to achieve the purpose of the solution of the present embodiment. One of ordinary skill in the art can understand and implement it without inventive effort.
Through the above description of the embodiments, those skilled in the art will clearly understand that each embodiment can be implemented by software plus a necessary general hardware platform, and certainly can also be implemented by hardware. With this understanding in mind, the above-described technical solutions may be embodied in the form of a software product, which can be stored in a computer-readable storage medium such as ROM/RAM, magnetic disk, optical disk, etc., and includes instructions for causing a computer device (which may be a personal computer, a server, or a network device, etc.) to execute the methods described in the embodiments or some parts of the embodiments.
Finally, it should be noted that: the above examples are only intended to illustrate the technical solution of the present invention, but not to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some technical features may be equivalently replaced; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions of the embodiments of the present invention.
Claims (10)
1. A method for monitoring hot spot information in the pharmaceutical industry is characterized by comprising the following steps:
acquiring medicine information of a target medicine enterprise;
monitoring a preset hot spot information element based on the medicine information, and marking the hot spot information element at the current time if the hot spot information element belongs to a first preset hot spot information set; and if the hotspot information element belongs to a second preset hotspot information set, acquiring a predicted time increment value corresponding to the target hotspot information element, and marking the hotspot information element based on the starting time of the hotspot information element in the second preset hotspot information set and the predicted time increment value.
2. The method for monitoring hot spot information in pharmaceutical industry according to claim 1, wherein the acquiring of the drug information of the target pharmaceutical enterprise comprises:
acquiring a marketed medical enterprise as a target medical enterprise based on a pre-constructed medical enterprise dictionary;
acquiring medicine information in research and development of a target medicine enterprise and marketed medicine information;
and acquiring core medicine information of the target medicine enterprise based on the medicine information in research and development and the marketed medicine information.
3. The method for monitoring hot spot information in pharmaceutical industry according to claim 2, wherein the core drug information comprises:
innovative drug information obtained based on drug information in research and development;
acquiring the market sales amount information of the marketed medicine, and acquiring the medicine information of which the sales amount ratio exceeds a preset threshold value based on the market sales amount information of the medicine.
4. The method for monitoring hot spot information in pharmaceutical industry according to claim 1, wherein if the hot spot information element belongs to a first preset hot spot information set, marking the hot spot information element with the current time comprises:
and acquiring a hotspot information element in the first preset hotspot information based on a preset time interval, and marking the target hotspot information element at the time acquired by the target hotspot information element.
5. The method for monitoring hot spot information in pharmaceutical industry according to claim 1, wherein if the hot spot information element belongs to a second preset hot spot information set, obtaining a predicted time increment value corresponding to the target hot spot information element, and marking the hot spot information element based on the start time of the hot spot information element in the second preset hot spot information set and the predicted time increment value comprises:
acquiring the starting time of the hotspot information element in the second preset hotspot information based on the marking time of the hotspot information element in the first preset hotspot information;
acquiring similar medicine information of target medicine information, and acquiring a predicted time increment value of a hotspot information element in second preset hotspot information based on historical data of the similar medicine information time increment value;
and marking the hot spot information elements in the second preset hot spot information based on the starting time and the predicted time increment of the hot spot information elements in the second preset hot spot information.
6. The method for monitoring hot spot information in the pharmaceutical industry according to any one of claims 1 to 5, wherein the hot spot information element in the first preset hot spot information is at least one element of a hot spot event of transaction, clinical application, clinical trial start, marketing application and sale influence;
and the hotspot information element in the second preset hotspot information is at least one element of clinical approval, clinical trial ending and approval marketing.
7. A method for monitoring hot spot information in pharmaceutical industry is characterized by further comprising the following steps:
pushing the hotspot information elements and the associated information thereof in the first preset hotspot information at the current marking time;
and pushing the hotspot information elements and the associated information thereof in the second preset hotspot information in a calendar mark mode.
8. A monitoring device for hot spot information in the pharmaceutical industry is characterized by comprising:
an information acquisition module: acquiring medicine information of a target medicine enterprise;
the information monitoring module: monitoring a preset hot spot information element based on the medicine information, and marking the hot spot information element at the current time if the hot spot information element belongs to a first preset hot spot information set; and if the hotspot information element belongs to a second preset hotspot information set, acquiring a predicted time increment value corresponding to the target hotspot information element, and marking the hotspot information element based on the starting time of the hotspot information element in the second preset hotspot information set and the predicted time increment value.
9. An electronic device comprising a memory, a processor and a computer program stored on the memory and executable on the processor, wherein the processor implements the steps of the method for monitoring medical industry hotspot information according to any one of claims 1 to 7 when executing the program.
10. A non-transitory computer readable storage medium, on which a computer program is stored, wherein the computer program, when being executed by a processor, implements the steps of the method for monitoring medical industry hotspot information according to any one of claims 1 to 7.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111665276.8A CN114358939A (en) | 2021-12-31 | 2021-12-31 | Method and device for monitoring hot spot information in pharmaceutical industry, electronic equipment and storage medium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111665276.8A CN114358939A (en) | 2021-12-31 | 2021-12-31 | Method and device for monitoring hot spot information in pharmaceutical industry, electronic equipment and storage medium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114358939A true CN114358939A (en) | 2022-04-15 |
Family
ID=81104593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111665276.8A Pending CN114358939A (en) | 2021-12-31 | 2021-12-31 | Method and device for monitoring hot spot information in pharmaceutical industry, electronic equipment and storage medium |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114358939A (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006040248A (en) * | 2004-06-23 | 2006-02-09 | Tomoaki Hirakawa | Stock investment information providing system and method |
| US20070269379A1 (en) * | 2003-07-23 | 2007-11-22 | Samir Mitragotri | Penetration Enhancer Combinations for Transdermal Delivery |
| CN101645067A (en) * | 2008-08-05 | 2010-02-10 | 北京大学 | Method for predicting hot forum in forum collection |
| CN101763401A (en) * | 2009-12-30 | 2010-06-30 | 暨南大学 | Network public sentiment hotspot prediction and analysis method |
| CN104620275A (en) * | 2012-07-19 | 2015-05-13 | 塞弗德公司 | Remote monitoring of medical devices |
| CN109285590A (en) * | 2018-08-07 | 2019-01-29 | 广州火龙果信息科技有限公司 | A kind of inpatient adverse drug events actively monitoring and assessment warning system |
| CN112489812A (en) * | 2020-11-30 | 2021-03-12 | 北京华彬立成科技有限公司 | Drug development analysis method, drug development analysis device, electronic device, and storage medium |
| CN113723826A (en) * | 2021-06-11 | 2021-11-30 | 北京华彬立成科技有限公司 | Method and device for monitoring early information of imitation drugs, electronic equipment and storage medium |
| CN113724085A (en) * | 2021-07-24 | 2021-11-30 | 北京华彬立成科技有限公司 | Mining method and device for early project information, electronic equipment and storage medium |
-
2021
- 2021-12-31 CN CN202111665276.8A patent/CN114358939A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070269379A1 (en) * | 2003-07-23 | 2007-11-22 | Samir Mitragotri | Penetration Enhancer Combinations for Transdermal Delivery |
| JP2006040248A (en) * | 2004-06-23 | 2006-02-09 | Tomoaki Hirakawa | Stock investment information providing system and method |
| CN101645067A (en) * | 2008-08-05 | 2010-02-10 | 北京大学 | Method for predicting hot forum in forum collection |
| CN101763401A (en) * | 2009-12-30 | 2010-06-30 | 暨南大学 | Network public sentiment hotspot prediction and analysis method |
| CN104620275A (en) * | 2012-07-19 | 2015-05-13 | 塞弗德公司 | Remote monitoring of medical devices |
| CN109285590A (en) * | 2018-08-07 | 2019-01-29 | 广州火龙果信息科技有限公司 | A kind of inpatient adverse drug events actively monitoring and assessment warning system |
| CN112489812A (en) * | 2020-11-30 | 2021-03-12 | 北京华彬立成科技有限公司 | Drug development analysis method, drug development analysis device, electronic device, and storage medium |
| CN113723826A (en) * | 2021-06-11 | 2021-11-30 | 北京华彬立成科技有限公司 | Method and device for monitoring early information of imitation drugs, electronic equipment and storage medium |
| CN113724085A (en) * | 2021-07-24 | 2021-11-30 | 北京华彬立成科技有限公司 | Mining method and device for early project information, electronic equipment and storage medium |
Non-Patent Citations (2)
| Title |
|---|
| 周志强;景惠玲;: "煤炭企业专利技术研发热点与前沿的可视化分析――以中国神华为例", 科技促进发展, no. 07, 20 July 2020 (2020-07-20) * |
| 王烨;程刚;: "某三级医院重点监控药品的使用情况分析", 中国当代医药, no. 24 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Best et al. | Individuals and organizations as sources of state effectiveness | |
| Oliveira‐Cruz et al. | Approaches to overcoming constraints to effective health service delivery: a review of the evidence | |
| Bucciol et al. | Purchasing medical devices: The role of buyer competence and discretion | |
| Thoma | Trademarks and the patent premium value: Evidence from medical and cosmetic products | |
| Zeng et al. | Improving fiscal space for health from the perspective of efficiency in low-and middle-income countries: What is the evidence? | |
| Starc et al. | Does entry remedy collusion? Evidence from the generic prescription drug cartel | |
| Nandy | Impact of R&D activities on the financial performance: Empirical evidence from Indian pharmaceutical companies | |
| CN114255877A (en) | Target point information mining and searching method and device, electronic equipment and storage medium | |
| Grennan et al. | Hospital management practices and medical device costs | |
| Wong et al. | Examination of clinical trial costs and barriers for drug development final | |
| Chen et al. | The positive externalities of IFRS R&D rule: Enhanced voluntary disclosure | |
| CN114358939A (en) | Method and device for monitoring hot spot information in pharmaceutical industry, electronic equipment and storage medium | |
| Panya et al. | Public procurement reforms in Africa: challenges, constraints and improvement opportunities | |
| CN113723826A (en) | Method and device for monitoring early information of imitation drugs, electronic equipment and storage medium | |
| Yao et al. | Price offers of pharmaceutical procurement in China: evidence from Guangdong province | |
| CN113674867A (en) | Clinical data mining method and device, electronic equipment and storage medium | |
| Tátrai et al. | Comparative Analysis of the European Centralised Public Procurement | |
| López-Mendoza et al. | Factors of technology transfer and its relation to success | |
| Ponnusamy et al. | Product Lifecycle in the Pharmaceutical Industry | |
| Boche et al. | Procurement Practice of Program Drugs and Its Challenges at the Ethiopian Pharmaceuticals Supply Agency: A Mixed Methods Study | |
| Liu | Deregulation on branded and generic drugs price and its effect: a study of Chinese pharmaceutical market | |
| Neyland et al. | Mundane market matters: On sensitive metrology and the governance of market-based interventions for global health | |
| Assunta Baldini et al. | Brand transaction announcements and stock price volatility | |
| CN114927232B (en) | Drug research and development type mining and searching method and device and electronic equipment | |
| Yang | Quantitative-Scientific Company and Product Scorecard Considerations and Modeling |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |